Windtree Competitors
| WINT Stock | USD 0.01 0.00 -0.000002% |
Windtree Therapeutics and Elevai Labs Correlation Overview
Almost no diversification
The correlation between WINT and ELAB is 0.94, which Macroaxis classifies as Almost no diversification for the selected horizon. Used correctly, the chart helps investors judge whether adding the second position genuinely diversifies the first.
Moving together with Windtree Stock
Moving against Windtree Stock
Mean reversion opportunities in Windtree Therapeutics' arise when market prices disconnect from fundamental anchors such as earnings, book value, or historical price-to-earnings multiples.
Windtree Therapeutics Competition Correlation Matrix
Correlation analysis between Windtree Therapeutics and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Windtree Stock performing well and Windtree Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Windtree Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| REVB | 4.02 | -1.48 | 0.00 | -0.80 | 0.00 | 5.56 | 34.09 | |||
| DRMA | 7.75 | -0.63 | 0.00 | -0.48 | 0.00 | 16.48 | 80.83 | |||
| ATXI | 8.76 | -0.99 | 0.00 | 0.34 | 0.00 | 20.97 | 122.38 | |||
| XRTX | 2.89 | -0.31 | 0.00 | 0.52 | 0.00 | 7.02 | 25.64 | |||
| VRAX | 5.84 | -0.38 | 0.00 | -0.12 | 0.00 | 10.00 | 92.80 | |||
| AIMD | 4.21 | -0.44 | 0.00 | -0.21 | 0.00 | 12.41 | 38.73 | |||
| NKGN | 15.02 | 6.42 | 0.22 | -0.99 | 9.08 | 35.14 | 298.33 | |||
| NCEL | 4.63 | -0.22 | 0.00 | 2.31 | 0.00 | 11.55 | 39.40 | |||
| GTBP | 4.62 | -0.57 | 0.00 | 3.31 | 0.00 | 8.33 | 37.01 | |||
| ELAB | 6.96 | -4.39 | 0.00 | -1.01 | 0.00 | 8.62 | 53.38 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Windtree Therapeutics financial statement analysis. It represents the amount of money remaining after all of Windtree Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Windtree Therapeutics and related stocks such as Revelation Biosciences, Dermata Therapeutics, and Avenue Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | -3.6 K | -136.4 K | -12 M | -10.8 M | -120.3 K | -15 M | -8.9 M | -8.5 M |
| DRMA | -4.7 M | -4.7 M | -4.7 M | -4.7 M | -4.7 M | -4.7 M | -4.7 M | -4.7 M | -4.7 M | -4.7 M | -3.2 M | -7.9 M | -9.6 M | -7.8 M | -12.3 M | -11.1 M | -11.6 M |
| XRTX | -36.9 K | -36.9 K | -36.9 K | -36.9 K | -36.9 K | -414.8 K | -414.8 K | -474.2 K | -3.8 M | -485.5 K | -1 M | -1.3 M | -7 M | -2.2 M | -4.8 M | -3.7 M | -3.5 M |
| VRAX | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -801.1 K | -651 K | -1.7 M | -5.5 M | -6.7 M | -6.1 M | -5.5 M | -5.7 M |
| AIMD | -300 K | -1.3 M | -650.8 K | -622.6 K | -622.6 K | -521.9 K | -670 K | -617.4 K | -1.3 M | -1.6 M | -1.5 M | -3.9 M | -14 M | -13.8 M | -14.9 M | -13.4 M | -12.7 M |
| NCEL | -6.7 M | -6.7 M | -6.7 M | -6.7 M | -6.7 M | -6.7 M | -6.7 M | -6.7 M | -5.1 K | -5.4 M | -2.9 M | -11.9 M | -16.5 M | -12.2 M | -2 M | -1.8 M | -1.9 M |
| GTBP | 150 K | -3.7 M | -5.2 M | -501 K | -23.5 M | -21.5 M | 9.8 M | -144.2 M | -259.2 M | -38.6 M | -28.3 M | -58 M | -20.9 M | -7.6 M | -13.2 M | -28.4 M | -26.9 M |
| ELAB | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -222.9 K | -784.7 K | -1.8 M | -4.3 M | -6.2 M | -5.6 M | -5.3 M |
Windtree Therapeutics Competitive Analysis
The better you understand Windtree Therapeutics competitive position, the more informed your investment decisions will be. Measuring Windtree Therapeutics' performance against peers across a range of fundamental indicators helps expose hidden risks and opportunities.| Better Than Average | Worse Than Peers | View Performance Chart |
Windtree Therapeutics Peer Performance Charts
How to Analyze Windtree Therapeutics Against Peers
Windtree Therapeutics' peer analysis compares Windtree Therapeutics with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Windtree Therapeutics trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Windtree Therapeutics leads or lags and what catalysts could close or widen the gap.